FDA grants priority review to Roche´s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
(WorldNews Switzerland)

Basel, 13 November 2018 FDA grants priority review to Roche`s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company`s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus...